These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17101825)

  • 21. Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients.
    Frisullo G; Nociti V; Iorio R; Katia Patanella A; Bianco A; Caggiula M; Sancricca C; Tonali PA; Mirabella M; Batocchi AP
    Clin Immunol; 2007 Sep; 124(3):284-93. PubMed ID: 17627892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
    Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
    Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
    Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
    Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IFNbeta therapy progressively normalizes the increased ex vivo T lymphocyte apoptosis observed in active patients with multiple sclerosis.
    García-Merino A; Barcenilla H; Díaz D; Monserrat J; Prieto A; Alvarez-Mon M;
    Clin Immunol; 2009 Aug; 132(2):195-202. PubMed ID: 19443275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic role of mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Pharmacol Ther; 2006 Jan; 109(1-2):198-209. PubMed ID: 16095713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Determination of a factor inhibiting migration of leukocytes to brain antigens, its concentration in serum and spontaneous leukocyte migration in multiple sclerosis].
    Loĭko TP; Ierusalimskiĭ AP; Lozovoĭ VP
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(2):187-90. PubMed ID: 3518311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A possible role of CD4+CD25+ T cells as well as transcription factor Foxp3 in the dysregulation of allergic rhinitis.
    Xu G; Mou Z; Jiang H; Cheng L; Shi J; Xu R; Oh Y; Li H
    Laryngoscope; 2007 May; 117(5):876-80. PubMed ID: 17473687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients.
    Pentón-Rol G; Cervantes-Llanos M; Cabrera-Gómez JA; Alonso-Ramírez R; Valenzuela-Silva C; Rodríguez-Lara R; Montero-Casimiro E; Bello-Rivero I; López-Saura P
    Int Immunopharmacol; 2008 Jun; 8(6):881-6. PubMed ID: 18442793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Earthworm fibrinolytic enzyme: anti-tumor activity on human hepatoma cells in vitro and in vivo.
    Chen H; Takahashi S; Imamura M; Okutani E; Zhang ZG; Chayama K; Chen BA
    Chin Med J (Engl); 2007 May; 120(10):898-904. PubMed ID: 17543180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].
    Ory S; Debouverie M; Le Page E; Pelletier J; Malikova I; Gout O; Roullet E; Vermersch P; Edan G
    Rev Neurol (Paris); 2008 Dec; 164(12):1028-34. PubMed ID: 18808781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?
    Bar-Or A; Oger J; Gibbs E; Niino M; Aziz T; Renoux C; Alatab S; Shi FD; Campagnolo D; Jalili F; Rhodes S; Yamashita T; Fan B; Freedman MS; Panitch H; Arnold DL; Vollmer T
    Mult Scler; 2009 Aug; 15(8):959-64. PubMed ID: 19667022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse.
    Mirowska-Guzel DM; Kurowska K; Skierski J; Koronkiewicz M; Wicha W; Kruszewska J; Czlonkowski A; Czlonkowska A
    J Neuroimmunol; 2006 Jul; 176(1-2):134-40. PubMed ID: 16723156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular targets for disrupting leukocyte trafficking during multiple sclerosis.
    McCandless EE; Klein RS
    Expert Rev Mol Med; 2007 Jul; 9(20):1-19. PubMed ID: 17637110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monomethylfumarate reduces in vitro migration of mononuclear cells.
    Dehmel T; Döbert M; Pankratz S; Leussink VI; Hartung HP; Wiendl H; Kieseier BC
    Neurol Sci; 2014 Jul; 35(7):1121-5. PubMed ID: 24504620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS.
    Chen M; Chen G; Nie H; Zhang X; Niu X; Zang YC; Skinner SM; Zhang JZ; Killian JM; Hong J
    Eur J Immunol; 2009 Sep; 39(9):2525-36. PubMed ID: 19670379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF).
    Lin SS; Lai KC; Hsu SC; Yang JS; Kuo CL; Lin JP; Ma YS; Wu CC; Chung JG
    Cancer Lett; 2009 Nov; 285(2):127-33. PubMed ID: 19477063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology?
    Johnson AJ; Suidan GL; McDole J; Pirko I
    Int Rev Neurobiol; 2007; 79():73-97. PubMed ID: 17531838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pravastatin in vivo reduces mononuclear cell migration through endothelial monolayers.
    Frigerio S; Gelati M; Boncoraglio G; Ciusani E; Croci D; de Curtis M; Parati E; Salmaggi A
    Neurol Sci; 2006 Sep; 27(4):261-5. PubMed ID: 16998730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.
    Cepok S; Schreiber H; Hoffmann S; Zhou D; Neuhaus O; von Geldern G; Hochgesand S; Nessler S; Rothhammer V; Lang M; Hartung HP; Hemmer B
    Arch Neurol; 2009 Oct; 66(10):1216-23. PubMed ID: 19667211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term experience with induction treatment regimens in multiple sclerosis.
    Le Page E; Edan G
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S46-9. PubMed ID: 19200867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.